Cooper. has filed a patent for a WS12-releasing contact lens that aims to increase comfort for symptomatic contact lens wearers by reducing dryness and increasing wearing time. The invention involves a polymeric lens body with WS12 adhered to it, releasing 0.05 µg to 0.5 µg of WS12 after 1 hour. GlobalData’s report on Cooper gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Cooper, was a key innovation area identified from patents. Cooper's grant share as of January 2024 was 53%. Grant share is based on the ratio of number of grants to total number of patents.
Contact lens releasing ws12 for comfort and dryness
See Also:
The patent application (Publication Number: US20240036354A1) describes an innovative unworn sterile hydrogel contact lens that includes a polymeric lens body with N-(4-methoxyphenyl)-5-methyl-2-(1-methylethyl)cyclohexane carboxamide (WS12) releasably adhered to it. The lens is immersed in a packaging solution and sealed in a package. The concentration of WS12 in the packaging solution is specified to be less than 0.05 µg/ml, ensuring controlled release of the compound. The contact lens is designed to sustain the release of WS12 for at least 6 hours, with specific release profiles ranging from 0.05 µg to 0.5 µg per hour for up to 6 hours. Additionally, the package containing the lens can be autoclaved for sterilization.
Furthermore, the patent application includes methods for correcting vision and alleviating dryness in contact lens wearers by using the described unworn sterile hydrogel contact lens. The application also outlines a manufacturing method for producing the lens, involving polymerization, extraction, hydration, and packaging steps. Additionally, a kit comprising multiple WS12-releasing contact lenses with varying amounts of WS12 adhered to them is detailed, offering a comprehensive solution for vision correction and dryness relief in contact lens wearers. The concentration of WS12 in the packaging solution for these lenses is maintained below 0.1 µg/ml, ensuring safety and efficacy. Overall, the patent application presents a novel approach to enhancing comfort and addressing common issues faced by contact lens wearers through the controlled release of WS12 in a sterile hydrogel lens system.
To know more about GlobalData’s detailed insights on Cooper, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
